Solventum Partners With Sprintray To Disrupt The Digital Dentistry Market With High-Quality, Permanent Same-Day Restorations

(MENAFN- PR Newswire) Solventum Dental Solutions connects leading-edge materials with data science to help dentists solve their toughest challenges with products such as FiltekTM Easy Match Universal Restorative, FiltekTM Matrix, ScotchbondTM Universal and RelyXTM Universal Cement. SprintRay offers innovative chairside end-to-end 3D printing ecosystems, which create a platform for a wide range of restorative dental applications.

With Solventum's legacy of best-in-class material science with leading restorative materials, and SprintRay's innovative technology, the partnership aims to bring to market the first permanent chairside, 3D printed crown. Together, Solventum and SprintRay anticipate improvement in patient experience and outcomes through fewer office visits – driving practice efficiency, and ultimately, delivering the outcomes patients and providers demand.

"Imagine a world where your dentist can create a crown that can last decades in a matter of minutes," said Karim Mansour, President, Dental Solutions, Solventum. "We believe this partnership will revolutionize the way dentists and orthodontists care for patients with in-office production, offering a simplified procedure that we anticipate will improve outcomes and experiences, reduce chair time and lower treatment costs. This collaboration allows us to integrate the latest technological advancements into our proven restorative solutions, ensuring we remain at the forefront of dental innovation to deliver unparalleled care to our patients."

Offering cutting-edge 3D printing technology directly to dentists and orthodontists will streamline care for patients and providers, allowing the delivery of same-visit dentistry and introducing a market for permanent 3D printed crowns, inlays, onlays and more.

"Together, we can make a significant impact in restorative dentistry by building exceptional products for same-visit treatment," said SprintRay CEO Amir Mansouri. "Our partnership with Solventum is a key collaboration and commitment to making a difference in people's oral health as well as enabling high-quality and cost-effective dental restorations across the globe."

The announcement of the partnership aligns with Solventum's legacy of quality material science and is one example of biasing resources towards growth while strengthening digital capabilities, two elements of Solventum's previously announced three-phased plan. As the winner of seven Dental Advisor awards in 2024, the partnership follows four new product introductions launched in 2024, including:

• 3MTM ClarityTM Precision Grip Attachments , the first 3D printed aligner attachments
• 3MTM ClinproTM Clear Fluoride Treatment , a new water-based formula for smoother application and a more comfortable patient experience
• ClarityTM Flex + Force Aligners , new proprietary multi-layer copolymer extruded in different thicknesses to best express varying degrees of movement
• 3MTM FiltekTM Easy Match Universal Restorative features naturally adaptive opacity and offers an intuitive shade selection process to simplify direct restorative procedures

Solventum will share more details about the strategic partnership at the International Dental Show (IDS) 2025 on March 26 in Cologne, Germany.

About Solventum
At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better - while empowering healthcare professionals to perform at their best. See how at Solventum.

Forward-Looking Statements
This news release contains forward-looking information about Solventum's financial results, estimates, and business prospects that involve substantial risks and uncertainties. In particular, statements regarding the future performance of Solventum, including guidance for 2024, are forward-looking statements. You can identify these statements by the use of words such as "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "guidance," "intends," "may," "outlook," "plans," "projects," "seeks," "sees," "should," "targets," "will," "would," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) the effects of, and changes in, worldwide economic, political, regulatory, international, trade and geopolitical conditions, natural disasters, war, public health crises, and other events beyond Solventum's control; (2) operational execution risks; (3) damage to our reputation or our brands; (4) risks from acquisitions, strategic alliances, divestitures and other strategic events; (5) ; the highly competitive environment in which Solventum operates and consolidation in the healthcare industry; (6) reduction in customers' research budgets or government funding; (7) the timing and market acceptance of Solventum's new product and service offerings; (8) ongoing working relationships with certain key healthcare professionals; (9) changes in reimbursement practices of governments or private payers or other cost containment measures; (10) Solventum's ability to obtain components or raw materials supplied by third parties and other manufacturing and related supply chain difficulties, interruptions, and disruptive factors; (11) risks related to the highly regulated environment in which Solventum operates; (12) Solventum's failure to obtain, maintain, protect, or effectively enforce its intellectual property ("IP") rights.

Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located under "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" in Solventum's periodic reports on file with the U.S. Securities & Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

SOURCE Solventum

MENAFN25032025003732001241ID1109356465